西罗莫司洗脱支架与其他冠脉支架治疗冠心病的临床安全性比较

摘要/Abstract

摘要： 目的对西罗莫司洗脱支架（SES）和其他冠脉支架治疗冠心病的临床安全性进行比较。方法通过文献检索国内外大型数据库如pubmed、OVID medline、sciencedirect、CNKI、万方数据库等，检索近5年发表的关于SES与裸金属支架及其他药物洗脱支架术后主要心脏不良事件（MACE）、靶血管重建率和靶病变重建率等终点的对比性研究。结果SES与裸金属支架相比，术后MACE明显下降，靶血管重建率和靶病变重建率也显著下降。SES与其他药物洗脱支架相比，临床安全性与紫杉醇洗脱支架（PES）相当，在某些患者（如合并糖尿病或冠脉分叉病变）可能优于佐他莫司洗脱支架（ZES）。对于合并肾功能不全的患者，SES同样优于BES，安全性与PES相当。C反应蛋白对于SES术后发生MACE可能具有预测价值。结论SES与裸金属支架相比，安全性明显提高，与PES相当。

关键词: 西罗莫司洗脱支架, 裸金属支架, 紫杉醇洗脱支架, 佐他莫司洗脱支架, 主要心脏不良事件, 靶血管重建率, 靶病变重建率。

Abstract: Objective To compare the clinical safety of sirolimus-eluting stent(SES) and other coronary stents in treating coronary artery disease. MethodsAll comparision study relating to the endpoints of SES in treating coronary artery disease published in the last five years, including major adverse cardiac events(MACE), target vessel revascularization(TVR), target lesion revascularization(TLR), are retrieved by indexing pubmed, OVID medline,sciencedirect, CNKI and Wanfang Data. ResultsCompared to bare-metal stent(BMS), the MACE of SES decreased obviously, at the same time TVR and TLR of SES dropped in significantly too. Contrasting to other drug-eluting stents, the clinical safety of SES was equal to PES, and better than ZES in some patients who had complications of diabetes mellitus or coronary bifurcation lesions. For patients with renal inadequacy, the clinical safety of SES was better than BMS and equal to PES. Perhaps C-reactive protein had a predictive value of the MACE incidence after SES implantation. ConclusionCompared to BMS, SES preferred to show a significantly higher safety which equals to PES.

Key words: sirolimus-eluting stent, bare-metal stent, paclitaxel-eluting stent, zotarolimus-eluting stents, major adverse cardiac events, target vessel revascularization, target lesion revascularization

刘威. 西罗莫司洗脱支架与其他冠脉支架治疗冠心病的临床安全性比较[J]. 中国药物警戒, 2012, 9(6): 363-366.

LIU Wei. The Clinical Safety Comparison Between Sirolimus-eluting Stent and Other Coronal Stents in Treating Coronary Artery Disease[J]. Chinese Journal of Pharmacovigilance, 2012, 9(6): 363-366.

参考文献

[1] Rahel BM,Laarman GJ,Kelder JC,et al.Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study)[J]. Am Heart J,2009,157(1): 149-155.
[2] 葛永贵,张大鹏,杨新春,等. 药物洗脱支架与金属裸支架在急性ST段抬高心肌梗死急诊介入治疗中应用长期随访结果的比较[J]. 中华心血管病杂志,2008,36(2):108-112.
[3] Umeda H,Iwase M,Gochi T,et al. Safety and efficacy of 2.5-mm sirolimus-eluting stent implantation at lower deployment pressures in very small vessels(<2.5 mm)[J].Coron Artery Dis, 2009, 20( 2): 163-168.
[4] Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial[J]. JACC Cardiovasc Interv, 2009, 2( 6): 515-523.
[5] Yoshikawa D,Isobe S,Umeda H,et al.Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents[J].Coron Artery Dis, 2009, 20(6): 422-427.
[6] Simsek C, Onuma Y, Magro M, et al. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease[J]. Catheter Cardiovasc Interv, 2010,76(1): 41-49.
[7] Rubartelli P, Petronio AS, Guiducci V,et al.Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial[J]. Eur Heart J ,2010;31(16): 2014-2020.
[8] Menichelli M,Parma A, Pucci E,et al.Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infa-rction(SESAMI)[J].J Am Coll Cardiol,2007,49(19): 1924-1930.
[9] Maeng M, Jensen LO,Galloe AM, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial[J]. Am J Cardiol,2009,103(3): 345-349.
[10] Sanfilippo A, Cumbo M, Caggegi AM, et al. Long-term outcomes comparison of different types of DES in elderly patients from a real-world experience[J].J Invasive Cardiol, 2009,21(7): 330-333.
[11] Kim HS, Lee JH, Lee SW, et al.Long-term safety and efficacy of sirolimus-vs.paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial[J].Int J Cardiol,2011,147(2): 253-257.
[12] Choi CU,Rha SW,Chen KY, et al.Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention[J].Circ J, 2009, 73(12): 2229-2235.
[13] Sukhija R, Aronow WS, Palaniswamy C, et al.Major adverse cardiac events in patients with moderate to severe renal insufficiency treated with first-generation drug-eluting stents[J]. Am J Cardiol, 2010,105( 3): 293-296.
[14] Kim HK,Jeong MH, Ahn YK, et al. Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction[J]. Am J Cardiol, 2010, 105(6): 813-818.
[15] Song YB, Hahn JY, Choi SH, et al.Sirolimus-versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS(Coronary Bifurcation Stenting) Registry[J]. J Am Coll Cardiol, 2010,55(16): 1743-1750.
[16] Hanna NN,Gaglia MA Jr, Torguson R, et al. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease(from the REWARDS Registry)[J]. Am J Cardiol, 2010, 106(4): 504-510.
[17] Ko YG, Kim JS, Choi D, et al.Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents: a propensity matched study: clinical evidence of late catch-up[J].Int J Cardiol, 2011, 152(3): 302-306.
[18] Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus:4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial[J]. JACC Cardiovasc Interv, 2011,4(3): 310-316.
[19] Kandzari DE,Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III(A Randomized Controlled Trial of the Medtronic Endeavor Drug[ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)[J].JACC Cardiovasc Interv,2011,4(5 ): 543-550.
[20] Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial[J]. Circulation, 2011, 123(24): 2819-2828.
[21] Rasmussen K,Maeng M,Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care(SORT OUT III): a randomised controlled superiority trial[J]. Lancet,2010,375(9720): 1090-1099.
[22] Waksman R,Buch AN, Torguson R, et al.Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry) [J]. Am J Cardiol, 2007,100(1): 45-51.
[23] Galloe AM,Thuesen L,Kelbaek H,et al.Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial[J].JAMA,2008,299(4): 409-416.